

## ASX ANNOUNCEMENT

28 August 2023

### Dr Julian Chick appointed as Chairman

---

**28 August 2023** – Cann Group Limited (ASX: CAN) (Cann or the Company) announces that Chairman, Allan McCallum, will retire from the board and Dr Julian Chick will be appointed to the role of Chairman effective midday, Monday, 28 August 2023.

As previously announced on 27 June 2023, Allan McCallum AO would retire from the board in the first quarter of the 2024 financial year.

These changes are part of a succession and renewal process to ensure the board-level skill-set continues to align with Cann's evolving transition to a more commercially focused business operating in specialised markets in Australia and overseas.

Dr Chick said, "On behalf of the Cann Group Board of Directors, I'd like to thank Allan for his leadership and commitment over the past nine years. He has overseen incredible progress, from first laying the foundations of Cann, to the public listing of the Company and through to the construction and now operation of our state-of-the-art Mildura facility. Cann is now ready to scale production of our high-quality, GMP product to the capacity this facility was built for and it's through Allan's guidance that this has been made possible."

**Authorised for release by the Board of Directors of the Company, Cann Group Limited.**

**For all media enquiries please contact:**

Jackson Paine  
Corporate Communications Manager  
+61 439 492 955  
[jackson.paine@canngrouponlimited.com](mailto:jackson.paine@canngrouponlimited.com)

**For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO and Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)